PMID- 12716485
OWN - NLM
STAT- MEDLINE
DCOM- 20031107
LR  - 20181130
IS  - 1079-9907 (Print)
IS  - 1079-9907 (Linking)
VI  - 23
IP  - 3
DP  - 2003 Mar
TI  - Association of HLA alleles with response (especially biochemical response) to 
      interferon therapy in Japanese patients with chronic hepatitis C.
PG  - 135-41
AB  - The response of chronic hepatitis C to interferon (IFN) treatment is classified 
      as complete response (CR), biochemical response (BR), or no response (NR). 
      Several studies have found no difference in prevention of hepatocellular 
      carcinoma by IFN therapy between patients with CR and those with BR. We 
      investigated whether specific human leukocyte antigen (HLA) alleles were 
      associated with response to IFN, especially BR, in 138 patients with chronic 
      hepatitis C. Comparing patients with and without CR, male, a low viral titer, 
      genotype 2a or 2b, HLA-B55, and HLA-DRB1-0803 were more common in the group with 
      CR. Multivariate analysis showed that age (adjusted odds ratio [OR], 0.95 by 
      every year [95% confidence interval [CI] 0.90 - 0.99], p = 0.028), genotype 2a or 
      2b (5.21 [95% CI 1.63 - 16.6], p = 0.005), and low viral titer (8.58 (2.66 - 
      27.7), p < 0.001) were associated with CR. Comparing patients with BR and NR, the 
      pretreatment alanine aminotransferase (ALT) level was lower in the BR group (p < 
      0.001). Both HLA-B7 and HLA-DRB1-0101 were more common in this group (p = 0.002). 
      As the alleles HLA-B7 and HLA-DRB1-0101 were in linkage disequilibrium, the 
      HLA-B7-DRB1-0101 haplotype may be associated with BR. Multivariate analysis 
      indicated that a low ALT level (0.98 by every 1 IU/L [95% CI 0.98 - 0.99], p = 
      0.001) and HLA-B7-DRB1-0101 haplotype (32.3 [95% CI 1.50 - 693.1], p = 0.026) 
      contributed significantly to BR. This study suggested that host HLA expression, 
      but not viral factors, can influence BR.
FAU - Nishiguchi, Shuhei
AU  - Nishiguchi S
AD  - Department of Hepatology, Osaka City University Graduate School of Medicine, 
      Osaka, Japan. snishiguch@med.osaka-cu.ac.jp
FAU - Kaneshiro, Satoshi
AU  - Kaneshiro S
FAU - Tanaka, Motoharu
AU  - Tanaka M
FAU - Enomoto, Masaru
AU  - Enomoto M
FAU - Akihiro, Tamori
AU  - Akihiro T
FAU - Habu, Daiki
AU  - Habu D
FAU - Takeda, Tadashi
AU  - Takeda T
FAU - Fujino, Keizo
AU  - Fujino K
FAU - Tanaka, Takashi
AU  - Tanaka T
FAU - Yano, Yoshihisa
AU  - Yano Y
FAU - Shiomi, Susumu
AU  - Shiomi S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the 
      International Society for Interferon and Cytokine Research
JID - 9507088
RN  - 0 (Antiviral Agents)
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
RN  - 0 (Recombinant Proteins)
RN  - 77238-31-4 (Interferon-beta)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - *Alleles
MH  - Antiviral Agents/administration & dosage/therapeutic use
MH  - Biomarkers/blood
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrosis/complications/drug therapy
MH  - Genotype
MH  - HLA Antigens/*genetics
MH  - HLA-A Antigens/genetics
MH  - HLA-DQ Antigens/genetics
MH  - HLA-DR Antigens/genetics
MH  - Hepacivirus/drug effects/genetics/isolation & purification
MH  - Hepatitis C, Chronic/*drug therapy/*genetics/pathology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Inflammation/drug therapy/etiology/pathology
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage/therapeutic use
MH  - Interferon-beta/administration & dosage/therapeutic use
MH  - Interferons/administration & dosage/*therapeutic use
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - RNA, Viral/blood/drug effects
MH  - Recombinant Proteins
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2003/04/30 05:00
MHDA- 2003/11/08 05:00
CRDT- 2003/04/30 05:00
PHST- 2003/04/30 05:00 [pubmed]
PHST- 2003/11/08 05:00 [medline]
PHST- 2003/04/30 05:00 [entrez]
AID - 10.1089/107999003321532466 [doi]
PST - ppublish
SO  - J Interferon Cytokine Res. 2003 Mar;23(3):135-41. doi: 
      10.1089/107999003321532466.